5.2.4. imaging. 5.2.4.1. magnetic resonance imaging multi-parametric mri combines t2-weighted, diffusion-weighted, dynamic contrast-enhanced imaging. although mri mainly initiated suspicion pca based psa and/or dre, also analysed initial test . besides suggesting presence pca, imaging also allows targeted prostate biopsy provides staging information. prostate cancer appears areas low signal intensity t2-weighted imaging, restriction diffusion early intense enhancement perfusion imaging. however, substantial overlap appearances pca prostate benign conditions. prostate imaging-reporting data system (pi-rads) proposed standardize interpretation stratify men suspected pca 1- 5- risk scale cspca . correlation rp specimens shows mri good sensitivity detection localisation isup grade group ≥ 2 cancers, especially diameter larger 10 mm . mri less sensitive identifying isup grade group 1 pca. identifies less 30% isup grade 1 cancers smaller 0.5 cc identified rp specimens histopathology analysis [182-185]. good sensitivity magnetic resonance imaging isup grade group ≥ 2 cancer confirmed patients underwent template biopsies. cochrane meta-analysis compared mri template biopsies (≥ 20 cores) biopsy-naïve repeat-biopsy settings, mri pooled sensitivity 0.91 (95% ci: 0.83–0.95) pooled specificity 0.37 (95% ci: 0.29–0.46) isup grade group > 2 cancers. isup grade ≥ 3 cancers, mri pooled sensitivity specificity 0.95 (95% ci: 0.87–0.99) 0.35 (95% ci: 0.26–0.46), respectively . meta-analysis seventeen studies involving men suspected biopsy-proven pca, average ppvs isup grade group ≥ 2 cancers lesions pi-rads version 2.1 score 3, 4 5 16% (7–27%), 59% (39–78%), 85% (73–94%), respectively, significant heterogeneity among studies . biopsy naïve men, mri-based indication biopsy referral, leads lower rates biopsy, lower rates men diagnosed pca labelled insignificant, men pca labelled cspca [121,186,188-190]. also true men prior negative biopsy (see section 5.4.2). 5.2.4.2. transrectal ultrasound ultrasound-based techniques standard trus reliable detecting pca diagnostic yield additional biopsies performed hypoechoic lesions negligible . new sonographic modalities micro-doppler, sonoelastography contrast-enhanced us provided promising preliminary findings, either alone, combined so-called ‘multi-parametric us’ . multi-parametric us vs. multi-parametric mri diagnose pca (cadmus) trial, 306 patients underwent multi-parametric mri multi-parametric us composed b-mode, colour doppler, real-time elastography, contrast-enhanced us. patients least one positive test underwent targeted biopsy. multi-parametric us detected 4.3% fewer cspca submitting 11.1% patients biopsy mri . high-resolution micro-us shows improved spatial resolution struggles assess anterior part large prostates. two prospective trials assessed mri micro-us interpreted blinded manner combined targeted systematic biopsy. one, mri micro-us detected respectively 60 (76%) 58 (73%) 79 cspcas, systematic sampling detected 45/79 cases (57%). mri-targeted biopsy detected seven cspcas missed micro-us; three anterior lesions. micro-us-guided biopsy detected five cspcas missed mri; these, three apex . study, mri- micro-us-targeted biopsy depicted cspca 37 (39%) 33 (35%) 94 men, respectively mri- plus micro-us-targeted pathway detected 38 cspca . findings suggest mri micro-us could complement other. micro-us could also interesting alternative mri/fusion since biopsy operators aware mri findings localise mri lesions micro-us and, thus, target direct us image guidance . note, evaluation micro-us inter-operator variability currently lacking. 5.2.4.3. prostate-specific antigen-positron emission tomography/computed tomography (or magnetic resonance imaging) though mainly used staging purposes, psma-pet/ct (or -pet/mri) prostate expression may used indicate target biopsies. cspca detection, pooled sensitivity 0.89 pooled specificity 0.56 reported . prospective trial 291 patients, combined psma + mri improved negative predicted value (npv) compared mri alone (91% vs. 72%, test ratio = 1.27 [1.11–1.39], p < 0.001). sensitivity also improved (97% vs. 83%, p < 0.001), specificity reduced (40% vs. 53%, p = 0.011) .